| Literature DB >> 36247481 |
Johannes Petersen1, Shiho Naito1, Benjamin Kloth1,2, Simon Pecha1, Svante Zipfel1, Yousuf Alassar1, Christian Detter1, Lenard Conradi1, Hermann Reichenspurner1, Evaldas Girdauskas1,2.
Abstract
Background: Minimally-invasive (MIS) mitral valve (MV) surgery has become standard therapy in many cardiac surgery centers. While femoral arterial perfusion is the preferred cannulation strategy in MIS mitral valve surgery, retrograde arterial perfusion is known to be associated with an increased risk for cerebral atheroembolism, particularly in atherosclerosis patients. Therefore, antegrade perfusion may be beneficial in such cases. This analysis aimed to compare outcomes of antegrade axillary vs. retrograde femoral perfusion in the MIS mitral valve surgery.Entities:
Keywords: antegrade perfusion; axillaris cannulation; minimally-invasive surgery; mitral vale surgery; mitral valve
Year: 2022 PMID: 36247481 PMCID: PMC9561617 DOI: 10.3389/fcvm.2022.980074
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
FIGURE 1Treatment strategy at our institution in patients with severe mitral valve (MV) disease planned for a minimally-invasive (MIC) mitral valve surgery.
FIGURE 2Example of a computed tomography (CT) scan of the aorta of a patient with severe arteriosclerosis in the axillary artery, aortic arch abdominal aorta and especially the femoral vessels in which minimally-invasive surgery was performed by using an antegrade arterial perfusion via arteria axillaris.
FIGURE 3Intraoperative situs of antegrade arterial perfusion via axillaris artery in minimally-invasive mitral valve surgery.
Preoperative patient characteristics: Antegrade axillary perfusion (group A) vs. retrograde femoral perfusion (group F).
| Patient characteristics | Group A ( | Group F ( | |
| Age (years) | 74.2 ± 5.8 | 73.9 ± 2.3 | 0.829 |
| Gender—male, | 29 (58) | 29 (58) | 1.000 |
| BMI, kg/m2 | 26.3 ± 3.9 | 24.4 ± 3.6 | 0.019 |
| Arterial hypertension, | 32 (64) | 35 (70) | 0.721 |
| Diabetes, | 7 (17) | 2 (4.4) | 0.041 |
| Dyslipidemia, | 12 (24) | 12 (24) | 1.000 |
| Smoking, | 6 (12) | 2 (4) | 0.144 |
| Preoperative endocarditis, | 4 (8) | 1 (2) | 0.075 |
| Prior Stroke, n (%) | 3 (6) | 1 (2) | 0.306 |
| Atrial Fibrillation, | 27 (54) | 13 (26) | 0.013 |
| Baseline LVEF (%) | 49.0 ± 9.3 | 55.4 ± 8.1 | 0.001 |
| EuroSCORE II | 3.99 ± 2.57 | 1.67 ± 1.58 | 0.001 |
| STS-Score | 2.19 ± 1.49 | 1.31 ± 0.64 | 0.023 |
BMI, Body Mass Index; EuroSCORE II, European System for Cardiac Operative Risk Evaluation; STS-Score, Society of Thoracic Surgeons-Score; LVEF, Left Ventricular Ejection Fraction.
Intraoperative patient data.
| Patient characteristics | Group A ( | Group F ( | |
| Mitral valve repair, | 42 (86) | 48 (96) | 0.067 |
| Concomitant procedures, | |||
| Left atrial ablation, | 5 (10) | 6 (12) | 1.000 |
| LAA closure, | 4 (8) | 1 (2) | 0.362 |
| Closure of PFO, | 0 | 2 (4) | 0.494 |
| Tricuspid valve repair, | 1 (2) | 0 | 1.000 |
| Cardiopulmonary bypass time (min) | 172 ± 46 | 178 ± 51 | 0.627 |
| Aortic Cross-Clamp-time (min) | 86 ± 20 | 111 ± 29 |
|
| Duration of surgery (min) | 260 ± 65 | 257 ± 69 | 0.870 |
LAA, Left atrial appendage; PFO, Persistent Foramen Ovale. Significant values are highlighted in bold.
Postoperative patient data.
| Patient characteristics | Group A ( | Group F ( | |
| Access site complications | 0 (0%) | 0 (0%) | 1.000 |
| Perioperative stroke | 0 (0%) | 0 (0%) | 1.000 |
| In-hospital mortality | 1 (2%) | 0 (0%) | 0.289 |
| Duration ICU stay (days) | 2.9 ± 2.6 | 2.1 ± 1.5 | 0.113 |
| Duration in-hospital stay (days) | 10.0 ± 4.4 | 7.1 ± 1.7 | <0.001 |
ICU, Intensive Care Unit.